Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism

被引:10
|
作者
Zhao, Bixiao [1 ]
Aggarwal, Abha [1 ]
Im, Soo-Yeon [2 ]
Viswanathan, Keya [1 ]
Landa, Inigo [2 ]
Nehs, Matthew A. [1 ]
机构
[1] Brigham & Womens Hosp, Dept Surg, Boston, MA USA
[2] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA USA
关键词
HIF-1; DIMERIZATION; ANTITUMOR-ACTIVITY; ACRIFLAVINE; CELLS;
D O I
10.1097/XCS.0000000000000226
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Anaplastic thyroid cancer (ATC) is an aggressive malignancy without effective treatments. ATC cells demonstrate upregulated glycolysis (Warburg effect), generating lactate that is subsequently exported by monocarboxylate transporter 4 (MCT4). This study aims to determine whether MCT4 inhibition can suppress ATC growth. STUDY DESIGN: ATC cell lines 8505C, JL30, and TCO1 were grown in low (3 mmol/L; LG) or high (25 mmol/L; HG) glucose medium containing the lactate shuttle inhibitors acriflavine (10-25 mu mol/L; ACF), syrosingopine (100 mu mol/L; SYR), or AZD3965 (20 mu mol/L; AZD). Lactate level and cell proliferation were measured with standard assays. Seahorse analysis was performed to determine glycolytic response. RESULTS: Compared with HG, addition of ACF to LG decreased lactate secretion for both 8505C (p < 10(-5)) and JL30 (p < 10(-4)) cells, whereas proliferation was also reduced (p < 10(-4) and 10(-5), respectively). During Seahorse analysis, addition of oligomycin increased acidification by 84 mpH/min in HG vs 10 mpH/min in LG containing ACF (p < 10(-5)). Treatment with LG and SYR drastically diminished 8505C and TCO1 growth vs HG (p < 0.01 for both). LG and AZD treatment also led to reduced proliferation in tested cell lines (p <= 0.01 for all) that was further decreased by addition of ACF (p < 10(-4) vs HG, p <= 0.01 vs LG and AZD). CONCLUSION: Inhibition of lactate shuttles significantly reduced proliferation and glycolytic capacity of ATC cells in a low-glucose environment. Targeting suppression of glycolytic and lactate processing pathways may represent an effective treatment strategy for ATC. (C) 2022 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1044 / 1050
页数:7
相关论文
共 50 条
  • [1] Inhibition of Glucose Metabolism with Metformin Decreases Tumor Proliferation and Migration in Anaplastic Thyroid Cancer
    Zhao, Bixiao
    Aggarwal, Abha
    Marshall, Jessica A.
    Nehs, Matthew A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : S77 - S77
  • [2] Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
    Marlow, Laura A.
    Reynolds, Lisa A.
    Cleland, Alan S.
    Cooper, Simon J.
    Gumz, Michelle L.
    Kurakata, Shinichi
    Fujiwara, Kosaku
    Zhang, Ying
    Sebo, Thomas
    Grant, Clive
    McIver, Bryan
    Wadsworth, J. Trad
    Radisky, Derek C.
    Smallridge, Robert C.
    Copland, John A.
    CANCER RESEARCH, 2009, 69 (04) : 1536 - 1544
  • [3] Synthetic lethal vulnerabilities stemming from inhibition of one carbon metabolism in anaplastic thyroid cancer
    Forrest, Alexander
    Ahsan, Anil
    Di Cristofano, Antonio
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
    Kurata, Kento
    Onoda, Naoyoshi
    Noda, Satoru
    Kashiwagi, Shinichiro
    Asano, Yuka
    Hirakawa, Kosei
    Ohira, Masaichi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2303 - 2308
  • [5] Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer
    Johnson, Jennifer M.
    Lai, Stephen Y.
    Cotzia, Paolo
    Cognetti, David
    Luginbuhl, Adam
    Pribitkin, Edmund A.
    Zhan, Tingting
    Mollaee, Mehri
    Domingo-Vidal, Marina
    Chen, Yunyun
    Campling, Barbara
    Bar-Ad, Voichita
    Birbe, Ruth
    Tuluc, Madalina
    Outschoorn, Ubaldo Martinez
    Curry, Joseph
    SEMINARS IN ONCOLOGY, 2015, 42 (06) : 915 - 922
  • [6] Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer
    Schiff, BA
    McMurphy, AB
    Jasser, SA
    Younes, MN
    Doan, D
    Yigitbasi, OG
    Kim, SW
    Zhou, G
    Mandal, M
    Bekele, BN
    Holsinger, FC
    Sherman, SI
    Yeung, SC
    El-Naggar, AK
    Myers, JN
    CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8594 - 8602
  • [7] Anaplastic thyroid cancer
    Neff, Ryan L.
    Farrar, William B.
    Kloos, Richard T.
    Burman, Kenneth D.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (02) : 525 - +
  • [8] Anaplastic thyroid cancer
    Pasieka, JL
    CURRENT OPINION IN ONCOLOGY, 2003, 15 (01) : 78 - 83
  • [9] Anaplastic thyroid cancer
    Ranganath, Rohit
    Shah, Manish A.
    Shah, Ashok R.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (05) : 387 - 391
  • [10] Anaplastic thyroid cancer
    O'Neill, James Paul
    Shaha, Ashok R.
    ORAL ONCOLOGY, 2013, 49 (07) : 702 - 706